Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Heide L Ford

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-PHARM General Operations
Phone303/724-3509

    Collapse Research 
    Collapse research activities and funding
    R41CA291231     (FORD, HEIDE L.)Aug 15, 2024 - Jul 31, 2025
    NIH
    Preclinical Studies to Develop an Eya2 Tyr Phosphatase Inhibitor as a Novel Medulloblastoma Therapeutic
    Role: Principal Investigator
    R01CA275187     (FORD, HEIDE L.)May 16, 2023 - Apr 30, 2028
    NIH
    Reprogramming myogenic regulatory factors in RMS to promote differentiation and halt growth
    Role: Principal Investigator
    R01CA224867     (FORD, HEIDE L.)Dec 1, 2018 - Nov 30, 2024
    NIH
    Deciphering Mechanisms by which Tumor Cells Collaborate to Mediate Metastasis
    Role: Principal Investigator
    R01NS108396     (FORD, HEIDE L.)Aug 1, 2018 - May 31, 2022
    NIH
    Examining the EYA2/MYC axis in Group 3 Medulloblastoma
    Role: Principal Investigator
    R01CA221282     (FORD, HEIDE L.)Aug 1, 2017 - Jul 31, 2022
    NIH
    Role of Eya3 in regulating the immune microenvironment to promote breast tumor progression
    Role: Principal Investigator
    R13CA216888     (FORD, HEIDE L.)Mar 3, 2017 - Mar 2, 2018
    NIH
    2017 Mammary Gland Biology Gordon Research Conference & Gordon Research Seminar
    Role: Principal Investigator
    R21CA201809     (FORD, HEIDE L.)Jul 1, 2016 - Jun 30, 2018
    NIH
    Using zebrafish to study the role of six1a/b and microRNA-30a in rhabdomyosarcoma (RMS) initiation and progression
    Role: Principal Investigator
    R21CA185752     (FORD, HEIDE L.)Dec 18, 2014 - Nov 30, 2016
    NIH
    Developing cancer therapies through targeting the Six1/Eya transcriptional complex
    Role: Principal Investigator
    R41CA180347     (FORD, HEIDE L.)Jul 17, 2013 - Mar 31, 2015
    NIH
    The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors
    Role: Principal Investigator
    R03DA033174     (ZHAO, RUI)Jul 15, 2011 - Jun 30, 2014
    NIH
    Identify inhibitors of the Six1/Eya interaction using high throughput screening
    Role: Co-Principal Investigator
    R01CA157790     (FORD, HEIDE L.)Apr 8, 2011 - Mar 31, 2016
    NIH
    The Six1/Eya Transcriptional complex as a mediator of lymphangiogenesis and lymph
    Role: Principal Investigator
    R03DA030559     (ZHAO, RUI)Jun 1, 2010 - May 31, 2012
    NIH
    Identify inhibitors of the Eya phosphatase activity using high throughput screeni
    Role: Co-Principal Investigator
    R01CA124545     (THORBURN, ANDREW M)Aug 1, 2008 - May 31, 2012
    NIH
    TRAIL Receptor Signaling in Human Tumors
    Role: Co-Principal Investigator
    R01CA095277     (FORD, HEIDE L.)Apr 1, 2002 - Dec 31, 2018
    NIH
    Role of Six1 and the miR106b 25 cluster in EMT and Tumor Progression
    Role: Principal Investigator
    F32CA079197     (FORD, HEIDE L)Mar 23, 1999
    NIH
    HSIX1 IN CANCER AND THE CELL CYCLE
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Souto EP, Gong P, Landua JD, Srinivasan RR, Ganesan A, Dobrolecki LE, Purdy SC, Pan X, Zeosky M, Chung A, Yi SS, Ford HL, Lewis MT. The interferon/STAT1 signaling axis is a common feature of tumor-initiating cells in breast cancer. bioRxiv. 2024 Aug 17. PMID: 37745510.
      View in: PubMed
    2. Alderman C, Krueger A, Rossi J, Ford HL, Zhao R. In Vitro Phosphatase Assays for the Eya2 Tyrosine Phosphatase. Methods Mol Biol. 2024; 2743:285-300. PMID: 38147222.
      View in: PubMed
    3. Wolin AR, Vincent MY, Hotz T, Purdy SC, Rosenbaum SR, Hughes CJ, Hsu JY, Oliphant MUJ, Armstrong B, Wessells V, Varella-Garcia M, Galbraith MD, Pierce A, Wang D, Venkataraman S, Danis E, Veo B, Serkova N, Espinosa JM, Gustafson DL, Vibhakar R, Ford HL. EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression. Neuro Oncol. 2023 12 08; 25(12):2287-2301. PMID: 37486991.
      View in: PubMed
    4. Hughes CJ, Fields KM, Danis EP, Hsu JY, Neelakantan D, Vincent MY, Gustafson AL, Oliphant MJ, Sreekanth V, Zaberezhnyy V, Costello JC, Jedlicka P, Ford HL. SIX1 and EWS/FLI1 co-regulate an anti-metastatic gene network in Ewing Sarcoma. Nat Commun. 2023 07 19; 14(1):4357. PMID: 37468459.
      View in: PubMed
    5. Wilson C, Mertens TC, Shivshankar P, Bi W, Collum SD, Wareing N, Ko J, Weng T, Naikawadi RP, Wolters PJ, Maire P, Jyothula SS, Thandavarayan RA, Ren D, Elrod ND, Wagner EJ, Huang HJ, Dickey BF, Ford HL, Karmouty-Quintana H. Sine oculis homeobox homolog 1 plays a critical role in pulmonary fibrosis. JCI Insight. 2022 05 23; 7(10). PMID: 35420997.
      View in: PubMed
    6. Hsu JY, Danis EP, Nance S, O'Brien JH, Gustafson AL, Wessells VM, Goodspeed AE, Talbot JC, Amacher SL, Jedlicka P, Black JC, Costello JC, Durbin AD, Artinger KB, Ford HL. SIX1 reprograms myogenic transcription factors to maintain the rhabdomyosarcoma undifferentiated state. Cell Rep. 2022 02 01; 38(5):110323. PMID: 35108532.
      View in: PubMed
    7. Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori G, Dedhar S, Derynck R, Ford HL, Fuxe J, Garc?a de Herreros A, Goodall GJ, Hadjantonakis AK, Huang RYJ, Kalcheim C, Kalluri R, Kang Y, Khew-Goodall Y, Levine H, Liu J, Longmore GD, Mani SA, Massagu? J, Mayor R, McClay D, Mostov KE, Newgreen DF, Nieto MA, Puisieux A, Runyan R, Savagner P, Stanger B, Stemmler MP, Takahashi Y, Takeichi M, Theveneau E, Thiery JP, Thompson EW, Weinberg RA, Williams ED, Xing J, Zhou BP, Sheng G. Author Correction: Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2021 Dec; 22(12):834. PMID: 34654908.
      View in: PubMed
    8. Anantharajan J, Baburajendran N, Lin G, Loh YY, Xu W, Ahmad NHB, Liu S, Jansson AE, Kuan JWL, Ng EY, Yeo YK, Hung AW, Joy J, Hill J, Ford HL, Zhao R, Keller TH, Kang C. Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphatase. Protein Sci. 2022 02; 31(2):422-431. PMID: 34761455.
      View in: PubMed
    9. Zhang G, Dong Z, Gimple RC, Wolin A, Wu Q, Qiu Z, Wood LM, Shen JZ, Jiang L, Zhao L, Lv D, Prager BC, Kim LJY, Wang X, Zhang L, Anderson RL, Moore JK, Bao S, Keller TH, Lin G, Kang C, Hamerlik P, Zhao R, Ford HL, Rich JN. Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe. J Exp Med. 2021 11 01; 218(11). PMID: 34617969.
      View in: PubMed
    10. Kong D, Zhou H, Neelakantan D, Hughes CJ, Hsu JY, Srinivasan RR, Lewis MT, Ford HL. VEGF-C mediates tumor growth and metastasis through promoting EMT-epithelial breast cancer cell crosstalk. Oncogene. 2021 02; 40(5):964-979. PMID: 33299122.
      View in: PubMed
    11. Zhou H, Zhang L, Vartuli RL, Ford HL, Zhao R. Corrigendum to "The Eya phosphatase: Its unique role in cancer" [Int. J. Biochem. Cell Biol. 96 (2018) 165-170]. Int J Biochem Cell Biol. 2020 Oct; 127:105847. PMID: 32933829.
      View in: PubMed
    12. Zhou H, Blevins MA, Hsu JY, Kong D, Galbraith MD, Goodspeed A, Culp-Hill R, Oliphant MUJ, Ramirez D, Zhang L, Trinidad-Pineiro J, Mathews Griner L, King R, Barnaeva E, Hu X, Southall NT, Ferrer M, Gustafson DL, Regan DP, D'Alessandro A, Costello JC, Patnaik S, Marugan J, Zhao R, Ford HL. Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis. Cancer Res. 2020 06 15; 80(12):2689-2702. PMID: 32341035.
      View in: PubMed
    13. Kong D, Hughes CJ, Ford HL. Cellular Plasticity in Breast Cancer Progression and Therapy. Front Mol Biosci. 2020; 7:72. PMID: 32391382.
      View in: PubMed
    14. Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori G, Dedhar S, Derynck R, Ford HL, Fuxe J, Garc?a de Herreros A, Goodall GJ, Hadjantonakis AK, Huang RYJ, Kalcheim C, Kalluri R, Kang Y, Khew-Goodall Y, Levine H, Liu J, Longmore GD, Mani SA, Massagu? J, Mayor R, McClay D, Mostov KE, Newgreen DF, Nieto MA, Puisieux A, Runyan R, Savagner P, Stanger B, Stemmler MP, Takahashi Y, Takeichi M, Theveneau E, Thiery JP, Thompson EW, Weinberg RA, Williams ED, Xing J, Zhou BP, Sheng G. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020 06; 21(6):341-352. PMID: 32300252.
      View in: PubMed
    15. Anantharajan J, Zhou H, Zhang L, Hotz T, Vincent MY, Blevins MA, Jansson AE, Kuan JWL, Ng EY, Yeo YK, Baburajendran N, Lin G, Hung AW, Joy J, Patnaik S, Marugan J, Rudra P, Ghosh D, Hill J, Keller TH, Zhao R, Ford HL, Kang C. Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells. Mol Cancer Ther. 2019 09; 18(9):1484-1496. PMID: 31285279.
      View in: PubMed
    16. Oliphant MUJ, Vincent MY, Galbraith MD, Pandey A, Zaberezhnyy V, Rudra P, Johnson KR, Costello JC, Ghosh D, DeGregori J, Espinosa JM, Ford HL. SIX2 Mediates Late-Stage Metastasis via Direct Regulation of SOX2 and Induction of a Cancer Stem Cell Program. Cancer Res. 2019 02 15; 79(4):720-734. PMID: 30606720.
      View in: PubMed
    17. Neelakantan D, Zhou H, Oliphant MUJ, Zhang X, Simon LM, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, Lewis MT, Ford HL. Publisher Correction: EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun. 2018 11 12; 9(1):4720. PMID: 30420638.
      View in: PubMed
    18. Zhang L, Zhou H, Li X, Vartuli RL, Rowse M, Xing Y, Rudra P, Ghosh D, Zhao R, Ford HL. Author Correction: Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression. Nat Commun. 2018 09 17; 9(1):3830. PMID: 30224630.
      View in: PubMed
    19. Vartuli RL, Zhou H, Zhang L, Powers RK, Klarquist J, Rudra P, Vincent MY, Ghosh D, Costello JC, Kedl RM, Slansky JE, Zhao R, Ford HL. Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. J Clin Invest. 2018 06 01; 128(6):2535-2550. PMID: 29757193.
      View in: PubMed
    20. Zhang L, Zhou H, Li X, Vartuli RL, Rowse M, Xing Y, Rudra P, Ghosh D, Zhao R, Ford HL. Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression. Nat Commun. 2018 03 13; 9(1):1047. PMID: 29535359.
      View in: PubMed
    21. Zhou H, Zhang L, Vartuli RL, Ford HL, Zhao R. The Eya phosphatase: Its unique role in cancer. Int J Biochem Cell Biol. 2018 03; 96:165-170. PMID: 28887153.
      View in: PubMed
    22. Neelakantan D, Zhou H, Oliphant MUJ, Zhang X, Simon LM, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, Lewis MT, Ford HL. EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun. 2017 06 12; 8:15773. PMID: 28604738.
      View in: PubMed
    23. Tavares ALP, Cox TC, Maxson RM, Ford HL, Clouthier DE. Negative regulation of endothelin signaling by SIX1 is required for proper maxillary development. Development. 2017 06 01; 144(11):2021-2031. PMID: 28455376.
      View in: PubMed
    24. Kendrick AA, Schafer J, Dzieciatkowska M, Nemkov T, D'Alessandro A, Neelakantan D, Ford HL, Pearson CG, Weekes CD, Hansen KC, Eisenmesser EZ. CD147: a small molecule transporter ancillary protein at the crossroad of multiple hallmarks of cancer and metabolic reprogramming. Oncotarget. 2017 Jan 24; 8(4):6742-6762. PMID: 28039486.
      View in: PubMed
    25. Dimberg LY, Towers CG, Behbakht K, Hotz TJ, Kim J, Fosmire S, Porter CC, Tan AC, Thorburn A, Ford HL. A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance. Mol Cancer Res. 2017 04; 15(4):382-394. PMID: 28108622.
      View in: PubMed
    26. Thorburn J, Staskiewicz L, Goodall ML, Dimberg L, Frankel AE, Ford HL, Thorburn A. Non-cell-autonomous Effects of Autophagy Inhibition in Tumor Cells Promote Growth of Drug-resistant Cells. Mol Pharmacol. 2017 Jan; 91(1):58-64. PMID: 27974637.
      View in: PubMed
    27. Zhou H, Neelakantan D, Ford HL. Clonal cooperativity in heterogenous cancers. Semin Cell Dev Biol. 2017 04; 64:79-89. PMID: 27582427.
      View in: PubMed
    28. Towers CG, Ford HL. A tale of two ends. Cell Cycle. 2016 06 17; 15(12):1523-4. PMID: 27101085.
      View in: PubMed
    29. Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MUJ, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, Ford HL. The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. Nat Commun. 2015 Dec 21; 6:10077. PMID: 26687066.
      View in: PubMed
    30. Drasin DJ, Guarnieri AL, Neelakantan D, Kim J, Cabrera JH, Wang CA, Zaberezhnyy V, Gasparini P, Cascione L, Huebner K, Tan AC, Ford HL. TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation. Cancer Res. 2015 May 01; 75(9):1908-21. PMID: 25716682.
      View in: PubMed
    31. Blevins MA, Towers CG, Patrick AN, Zhao R, Ford HL. The SIX1-EYA transcriptional complex as a therapeutic target in cancer. Expert Opin Ther Targets. 2015 Feb; 19(2):213-25. PMID: 25555392.
      View in: PubMed
    32. Wang CA, Harrell JC, Iwanaga R, Jedlicka P, Ford HL. Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3. Breast Cancer Res. 2014 Oct 30; 16(5):462. PMID: 25358638.
      View in: PubMed
    33. Wang CA, Drasin D, Pham C, Jedlicka P, Zaberezhnyy V, Guney M, Li H, Nemenoff R, Costello JC, Tan AC, Ford HL. Homeoprotein Six2 promotes breast cancer metastasis via transcriptional and epigenetic control of E-cadherin expression. Cancer Res. 2014 Dec 15; 74(24):7357-70. PMID: 25348955.
      View in: PubMed
    34. Neelakantan D, Drasin DJ, Ford HL. Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis. Cell Adh Migr. 2015; 9(4):265-76. PMID: 25482627.
      View in: PubMed
    35. Krueger AB, Drasin DJ, Lea WA, Patrick AN, Patnaik S, Backos DS, Matheson CJ, Hu X, Barnaeva E, Holliday MJ, Blevins MA, Robin TP, Eisenmesser EZ, Ferrer M, Simeonov A, Southall N, Reigan P, Marugan J, Ford HL, Zhao R. Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migration. J Biol Chem. 2014 Jun 06; 289(23):16349-61. PMID: 24755226.
      View in: PubMed
    36. O'Brien JH, Hernandez-Lagunas L, Artinger KB, Ford HL. MicroRNA-30a regulates zebrafish myogenesis through targeting the transcription factor Six1. J Cell Sci. 2014 May 15; 127(Pt 10):2291-301. PMID: 24634509.
      View in: PubMed
    37. Kohrt D, Crary J, Zimmer M, Patrick AN, Ford HL, Hinds PW, Grossel MJ. CDK6 binds and promotes the degradation of the EYA2 protein. Cell Cycle. 2014; 13(1):62-71. PMID: 24196439.
      View in: PubMed
    38. Cieply B, Farris J, Denvir J, Ford HL, Frisch SM. Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2. Cancer Res. 2013 Oct 15; 73(20):6299-309. PMID: 23943797.
      View in: PubMed
    39. Patrick AN, Cabrera JH, Smith AL, Chen XS, Ford HL, Zhao R. Structure-function analyses of the human SIX1-EYA2 complex reveal insights into metastasis and BOR syndrome. Nat Struct Mol Biol. 2013 Apr; 20(4):447-53. PMID: 23435380.
      View in: PubMed
    40. Krueger AB, Dehdashti SJ, Southall N, Marugan JJ, Ferrer M, Li X, Ford HL, Zheng W, Zhao R. Identification of a selective small-molecule inhibitor series targeting the eyes absent 2 (Eya2) phosphatase activity. J Biomol Screen. 2013 Jan; 18(1):85-96. PMID: 22820394.
      View in: PubMed
    41. Iwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP, Ford HL. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res. 2012 Jul 05; 14(4):R100. PMID: 22765220.
      View in: PubMed
    42. Robin TP, Smith A, McKinsey E, Reaves L, Jedlicka P, Ford HL. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Mol Cancer Res. 2012 Aug; 10(8):1098-108. PMID: 22723308.
      View in: PubMed
    43. Smith AL, Robin TP, Ford HL. Molecular pathways: targeting the TGF-? pathway for cancer therapy. Clin Cancer Res. 2012 Sep 01; 18(17):4514-21. PMID: 22711703.
      View in: PubMed
    44. Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene. 2013 Mar 14; 32(11):1341-50. PMID: 22580613.
      View in: PubMed
    45. Wang CA, Jedlicka P, Patrick AN, Micalizzi DS, Lemmer KC, Deitsch E, Cas?s-Selves M, Harrell JC, Ford HL. SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer. J Clin Invest. 2012 May; 122(5):1895-906. PMID: 22466647.
      View in: PubMed
    46. Qamar L, Deitsch E, Patrick AN, Post MD, Spillman MA, Iwanaga R, Thorburn A, Ford HL, Behbakht K. Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer. Gynecol Oncol. 2012 May; 125(2):451-7. PMID: 22333994.
      View in: PubMed
    47. Drasin DJ, Robin TP, Ford HL. Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity. Breast Cancer Res. 2011; 13(6):226. PMID: 22078097.
      View in: PubMed
    48. Menke C, Bin L, Thorburn J, Behbakht K, Ford HL, Thorburn A. Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents. Cancer Res. 2011 Mar 01; 71(5):1883-92. PMID: 21363923.
      View in: PubMed
    49. Menke C, Goncharov T, Qamar L, Korch C, Ford HL, Behbakht K, Thorburn A. TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro. PLoS One. 2011 Jan 14; 6(1):e14527. PMID: 21264287.
      View in: PubMed
    50. Micalizzi DS, Wang CA, Farabaugh SM, Schiemann WP, Ford HL. Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth. Cancer Res. 2010 Dec 15; 70(24):10371-80. PMID: 21056993.
      View in: PubMed
    51. Ford HL, Thompson EW. Mammary gland studies as important contributors to the cause of epithelial mesenchymal plasticity in malignancy. J Mammary Gland Biol Neoplasia. 2010 Jun; 15(2):113-5. PMID: 20544376.
      View in: PubMed
    52. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010 Jun; 15(2):117-34. PMID: 20490631.
      View in: PubMed
    53. Coletta RD, McCoy EL, Burns V, Kawakami K, McManaman JL, Wysolmerski JJ, Ford HL. Characterization of the Six1 homeobox gene in normal mammary gland morphogenesis. BMC Dev Biol. 2010 Jan 14; 10:4. PMID: 20074369.
      View in: PubMed
    54. Micalizzi DS, Ford HL. Epithelial-mesenchymal transition in development and cancer. Future Oncol. 2009 Oct; 5(8):1129-43. PMID: 19852726.
      View in: PubMed
    55. McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, Ford HL. Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest. 2009 Sep; 119(9):2663-77. PMID: 19726883.
      View in: PubMed
    56. Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Bar?n AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, Schiemann WP, Ford HL. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest. 2009 Sep; 119(9):2678-90. PMID: 19726885.
      View in: PubMed
    57. Patrick AN, Schiemann BJ, Yang K, Zhao R, Ford HL. Biochemical and functional characterization of six SIX1 Branchio-oto-renal syndrome mutations. J Biol Chem. 2009 Jul 31; 284(31):20781-90. PMID: 19497856.
      View in: PubMed
    58. McCoy EL, Kawakami K, Ford HL, Coletta RD. Expression of Six1 homeobox gene during development of the mouse submandibular salivary gland. Oral Dis. 2009 Sep; 15(6):407-13. PMID: 19371398.
      View in: PubMed
    59. Coletta RD, Christensen KL, Micalizzi DS, Jedlicka P, Varella-Garcia M, Ford HL. Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation. Cancer Res. 2008 Apr 01; 68(7):2204-13. PMID: 18381426.
      View in: PubMed
    60. Christensen KL, Patrick AN, McCoy EL, Ford HL. The six family of homeobox genes in development and cancer. Adv Cancer Res. 2008; 101:93-126. PMID: 19055944.
      View in: PubMed
    61. Behbakht K, Qamar L, Aldridge CS, Coletta RD, Davidson SA, Thorburn A, Ford HL. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res. 2007 Apr 01; 67(7):3036-42. PMID: 17409410.
      View in: PubMed
    62. Christensen KL, Brennan JD, Aldridge CS, Ford HL. Cell cycle regulation of the human Six1 homeoprotein is mediated by APC(Cdh1). Oncogene. 2007 May 17; 26(23):3406-14. PMID: 17130831.
      View in: PubMed
    63. Miller MM, Wang C, Parisini E, Coletta RD, Goto RM, Lee SY, Barral DC, Townes M, Roura-Mir C, Ford HL, Brenner MB, Dascher CC. Characterization of two avian MHC-like genes reveals an ancient origin of the CD1 family. Proc Natl Acad Sci U S A. 2005 Jun 14; 102(24):8674-9. PMID: 15939884.
      View in: PubMed
    64. Reichenberger KJ, Coletta RD, Schulte AP, Varella-Garcia M, Ford HL. Gene amplification is a mechanism of Six1 overexpression in breast cancer. Cancer Res. 2005 Apr 01; 65(7):2668-75. PMID: 15805264.
      View in: PubMed
    65. Coletta RD, Christensen K, Reichenberger KJ, Lamb J, Micomonaco D, Huang L, Wolf DM, M?ller-Tidow C, Golub TR, Kawakami K, Ford HL. The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci U S A. 2004 Apr 27; 101(17):6478-83. PMID: 15123840.
      View in: PubMed
    66. Coletta RD, Jedlicka P, Gutierrez-Hartmann A, Ford HL. Transcriptional control of the cell cycle in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia. 2004 Jan; 9(1):39-53. PMID: 15082917.
      View in: PubMed
    67. Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS, Zahnow CA, Patterson N, Golub TR, Ewen ME. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 2003 Aug 08; 114(3):323-34. PMID: 12914697.
      View in: PubMed
    68. Wang C, Perera TV, Ford HL, Dascher CC. Characterization of a divergent non-classical MHC class I gene in sharks. Immunogenetics. 2003 Apr; 55(1):57-61. PMID: 12715247.
      View in: PubMed
    Ford's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (312) concept(s)
    _
    Co-Authors Expand Description
    See all (38) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)